The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 10, 2017

Filed:

Jun. 13, 2014
Applicants:

Myrna Cristina Bonaldo, Rio de Janeiro, BR;

Ricardo Galler, Niteroi, BR;

Inventors:

Myrna Cristina Bonaldo, Rio de Janeiro, BR;

Ricardo Galler, Niteroi, BR;

Assignee:

Other;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/12 (2006.01); C07K 14/005 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/12 (2013.01); C07K 14/005 (2013.01); A61K 2039/525 (2013.01); A61K 2039/5256 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C12N 2770/24122 (2013.01); C12N 2770/24134 (2013.01); C12N 2770/24143 (2013.01);
Abstract

The purpose of the present invention is the production of recombinant virus through the cloning and expression of sequences of coding nucleotides of the whole or part of heterolog proteins, through the following method: (a) modification of the heterolog nucleotides sequences in such way that when cloned and expressed in the vector virus, they present in the 5' region nucleotides present in the 5′ edge of the gene NS1 of this vector virus or of other virus or equivalent functional sequences, and in its 3′ region, the correspondent genome region in the whole or part of the spheres of the stem and anchor of the protein E of this vector virus or equivalent functional sequences, and not comprising the structure and the replication of the mention vector virus; (b) insertion of the modified heterolog sequences in (a) in the intergene region at the structural protein E level and of nonstructural NS1 vector virus; (c) obtaining the non-pathogenic recombinant virus and owner of the immunologic properties, having the heterolog sequences integrated in the viral genome according to the insertion described in (b) and, like that, expressing the heterolog antigen in such way that it can induce an appropriate immune response. The present invention is also addressed to vaccine compositions to immune against the Flavivirus and/or other pathogens.


Find Patent Forward Citations

Loading…